Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
AGPS Biologics Sequence Review Report 2026: Alkyldihydroxyacetonephosphate synthase, peroxisomal Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of AGPS protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PLK4 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase PLK4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PLK4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PIK3CD Biologics Sequence Review Report 2026: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PIK3CD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CDC7 Biologics Sequence Review Report 2026: Cell division cycle 7-related protein kinase Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CDC7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TK2 Biologics Sequence Review Report 2026: Thymidine kinase 2, mitochondrial Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TK2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EEF2K Biologics Sequence Review Report 2026: Eukaryotic elongation factor 2 kinase Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EEF2K protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SGK1 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Sgk1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of SGK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD38 Biologics Sequence Review Report 2026: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD38 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHEK2 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
BUB1B Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
BUB1 Biologics Sequence Review Report 2026: Mitotic checkpoint serine/threonine-protein kinase BUB1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of BUB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHEK1 Biologics Sequence Review Report 2026: Serine/threonine-protein kinase Chk1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CHEK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.